Abbonarsi

Accuracy of penicillin allergy diagnostic tests: A systematic review and meta-analysis - 09/01/21

Doi : 10.1016/j.jaci.2020.04.058 
Bernardo Sousa-Pinto, PhD a, b, c, , Isabel Tarrio, MD a, , Kimberly G. Blumenthal, MD d, e, Luís Araújo, MD b, c, Luís Filipe Azevedo, PhD a, b, Luís Delgado, PhD b, c, João Almeida Fonseca, PhD a, b
a MEDCIDS, Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal 
b CINTESIS, Center for Health Technology and Services Research, Faculty of Medicine, University of Porto, Porto, Portugal 
c Basic and Clinical Immunology Unit, Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal 
d Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Mass 
e Harvard Medical School, Boston, Mass 

Corresponding author: Bernardo Sousa-Pinto, PhD, CINTESIS, Center for Health Technology and Services Research, Rua Dr. Placido da Costa, Porto, Portugal.CINTESISCenter for Health Technology and Services ResearchRua Dr. Placido da CostaPortoPortugal

Abstract

Background

Having a penicillin allergy label associates with a higher risk for antibiotic resistance and increased health care use.

Objective

We sought to assess the accuracy of skin tests and specific IgE quantification in the diagnostic evaluation of patients reporting a penicillin/β-lactam allergy.

Methods

We performed a systematic review and diagnostic accuracy meta-analysis, searching on MEDLINE, Scopus, and Web of Science. We included studies conducted in patients reporting a penicillin allergy and in whom skin tests and/or specific IgE quantification were performed and compared with drug challenge results. We quantitatively assessed the accuracy of diagnostic tests with bivariate random-effects meta-analyses. Meta-regression and subgroup analyses were performed to explore causes of heterogeneity. Studies’ quality was evaluated using QUADAS-2 criteria.

Results

We included 105 primary studies, assessing 31,761 participants. Twenty-seven studies were assessed by bivariate meta-analysis. Skin tests had a summary sensitivity of 30.7% (95% CI, 18.9%-45.9%) and a specificity of 96.8% (95% CI, 94.2%-98.3%), with a partial area under the summary receiver-operating characteristic curve of 0.686 (I2 = 38.2%). Similar results were observed for subanalyses restricted to patients reporting nonimmediate maculopapular exanthema or urticaria/angioedema. Specific IgE had a summary sensitivity of 19.3% (95% CI, 12.0%-29.4%) and a specificity of 97.4% (95% CI, 95.2%-98.6%), with a partial area under the summary receiver-operating characteristic curve of 0.420 (I2 = 8.5%). Projected predictive values mainly reflect the low frequency of true penicillin allergy.

Conclusions

Skin tests and specific IgE quantification appear to have low sensitivity and high specificity. Because current evidence is insufficient for assessing the role of these tests in stratifying patients for delabeling, we identified key requirements needed for future studies.

Il testo completo di questo articolo è disponibile in PDF.

Graphical abstract




Il testo completo di questo articolo è disponibile in PDF.

Key words : Diagnostic accuracy, drug provocation test, IgE quantification, penicillin allergy, skin tests

Abbreviations used : AUC-sROC, DPT, NPV, PPV, sIgE


Mappa


 This work was supported by the Portuguese Ministry for Science, Technology and Higher Education (Ministério da Ciência, Tecnologia e Ensino Superior), through the Portuguese Foundation for Science and Technology (Fundação para a Ciência e a Tecnologia; grant no. PD/BD/129836/2017). K.G.B. receives career development support from the National Institutes of Health (grant no. NIH K01AI125631), the American Academy of Audiology, Asthma & Immunology Foundation, and the Massachusetts General Hospital (MGH) Claflin Distinguished Scholar Award.
 Disclosure of potential conflict of interest: K. G. Blumenthal has a clinical decision support tool for inpatient beta-lactam allergy evaluation used at Partners HealthCare Systems and licensed to Persistent Systems, and receives career development support from the National Institutes of Health (grant no. NIH K01AI125631), the American Academy of Allergy, Asthma, & Immunology (AAAAI) Foundation, and the Massachusetts General Hospital (MGH) Claflin Distinguished Scholar Award. The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health, the AAAAI Foundation, or the MGH. The rest of the authors declare that they have no relevant conflicts of interest.


© 2020  American Academy of Allergy, Asthma & Immunology. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 147 - N° 1

P. 296-308 - Gennaio 2021 Ritorno al numero
Articolo precedente Articolo precedente
  • IL-4–BATF signaling directly modulates IL-9 producing mucosal mast cell (MMC9) function in experimental food allergy
  • Sunil Tomar, Varsha Ganesan, Ankit Sharma, Chang Zeng, Lisa Waggoner, Andrew Smith, Chang H. Kim, Paula Licona-Limón, Richard L. Reinhardt, Richard A. Flavell, Yui-Hsi Wang, Simon P. Hogan
| Articolo seguente Articolo seguente
  • Efficacy and safety of anti-CD45–saporin as conditioning agent for RAG deficiency
  • Maria Carmina Castiello, Marita Bosticardo, Nicolò Sacchetti, Enrica Calzoni, Elena Fontana, Yasuhiro Yamazaki, Elena Draghici, Cristina Corsino, Ileana Bortolomai, Lucia Sereni, Hsin-Hui Yu, Paolo Uva, Rahul Palchaudhuri, David T. Scadden, Anna Villa, Luigi D. Notarangelo

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.